Loading...
NPI 1861763658 · Hammond, IN · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Alverno Laboratories, LLC is a clinical medical laboratory provider located in Hammond, Indiana. This profile covers 363 Medicare and 241 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Alverno Laboratories, LLC |
| Address | 2434 Interstate Plaza Dr. |
| City | Hammond |
| State | IN |
| ZIP | 46324 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | January 25, 2012 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $33.9M |
| Medicare | $8.1M |
ALVERNO LABORATORIES, LLC operates as a high-volume clinical diagnostic laboratory: its Medicare top revenue drivers are procedural and routine diagnostic tests such as 36415 (venipuncture), 80053 (CMP), and 80061 (lipid panel), and the Medicaid top codes include high-throughput molecular and infectious disease assays such as U0003 (SARS‑CoV‑2 NAAT), 87591 (GC NAAT), and 87491 (Chlamydia NAAT). The mix of routine chemistry/hematology (80053, 80061, 85025), endocrine and vitamin tests (84443, 82306), plus extensive NAAT and infectious‑disease codes in Medicaid indicates the lab offers both large-scale phlebotomy/specimen accessioning and molecular testing capacity.
Revenue concentration differs by payer: the top three Medicare codes by revenue account for 36.5% of the provider's total Medicare revenue, indicating a meaningful concentration in a small group of high-volume routine services; for Medicaid the top three codes by revenue account for 25.0% of total Medicaid revenue, showing somewhat broader distribution across many high-volume public‑payer services. These precomputed shares suggest Medicare income is concentrated around a few staple lab procedures while Medicaid revenue is more distributed among multiple high-revenue infectious disease and screening assays.
Payer mix is heavily weighted to Medicaid: lifetime Medicare revenue is $8.1M versus lifetime Medicaid revenue of $33.9M, so Medicaid represents the dominant payer relationship in scale for this provider. That imbalance implies state Medicaid contracts or referral streams are likely the primary commercial driver for overall volume and growth opportunities rather than Medicare alone.
National competitive standing on Medicare shows extreme volume concentration for many routine codes: 36415 ranks #43 of 86467 (100th percentile; extreme outlier), 80053 ranks #50 of 26416 (100th percentile; extreme outlier), and 80061 ranks #43 of 21671 (100th percentile; extreme outlier). These national ranks indicate ALVERNO produces far higher-than‑typical Medicare volumes for multiple standard lab procedures, consistent with a centralized collection/processing operation serving many patients or external collection sites.
State-level competitive standing on Medicaid is dominant for numerous codes: 87389, 84443, 80053, 80050, 82306, 80061, 88175, 87624, 83036 and several others rank #1 in-state (100th percentile; extreme outlier), while 87591 and 87491 rank #2 in-state (99th percentile; extreme outlier). This pattern demonstrates ALVERNO is a leading Medicaid laboratory in its state across STI, screening, cytology, and routine panel testing and likely captures a substantial share of public‑payer specimen volume.
Molecular and infectious‑disease testing is a material business line in Medicaid: high Medicaid revenues are concentrated in U0003 ($2.3M, ranks #5 of 89 in-state, 95th percentile; notably above typical state volume), 87591 ($2M, ranks #2 of 112, 99th percentile; extreme outlier), 87491 ($2M, ranks #2 of 111, 99th percentile; extreme outlier), and multiple other NAAT/viral codes (87801, 87637, U0005). The prominence of these molecular codes signals capacity for high-throughput NAAT workflows that drive substantial Medicaid revenue.
Operational profile implied by the code mix: large claim counts for specimen collection and routine panels (e.g., 36415 with 98.1K Medicare claims and 153.3K Medicaid claims) alongside very large Medicaid volumes for screening and NAATs (e.g., 214.8K claims for 80053 and 216.8K claims for 85025 in Medicaid) point to broad outpatient collection reach and integration with community providers or public health clinics. In practice, this suggests ALVERNO functions as a regional reference lab that handles both high-touch specimen collection and automated high-throughput analytic testing lines.
Tenure and regulatory footprint: the NPI was enumerated on 2012-01-25 (~14 years ago), giving the organization over a decade of documented claims activity; combined with the sustained, high volumes reported across both Medicare and Medicaid, this tenure supports the conclusion that ALVERNO is an established laboratory with stable, high-throughput operations across multiple payer channels.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
363 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 98,130 | $10 | $785K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 77,520 | $10 | $775.2K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 59,590 | $10 | $774.6K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 44,230 | $20 | $707.7K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 22,440 | $30 | $650.7K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 66,550 | $10 | $532.4K |
| 83036 | Sugar in the bloodstream can get attached to the hemoglobin in red blood cells. Once the sugar is attached, it stays there for the lifetime of the red blood cell (around 120 days or over 3 months).… | 33,390 | $10 | $300.5K |
| 82607 | The lab analyst performs a test to measure the amount of vitamin B12 in a patient specimen, typically in patient blood. | 15,970 | $20 | $239.5K |
| 83970 | Parathyroid hormone test measures the level of PTH in the blood. This test is done to ascertain the level of calcium and evaluate the parathyroid function. | 4,010 | $40 | $160.5K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 7,510 | $20 | $142.7K |
Showing 1–10 of 363
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 363 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
363 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87798 | 7 | 10 | 540 | $30 | $780.8K |
| 87641 | 2 | 10 | 300 | $30 | $113.7K |
| 87640 | 4 | 10 | 30 | $30 | $79.5K |
| 88305 | 20 | 230 | 700 | $30 | $39.7K |
| G0480 | 15 | 50 | 100 | $110 | $39.4K |
| U0003 | 4 | 10 | 250 | $70 | $38.8K |
| G0472 | 1 | 10 | 810 | $50 | $36.9K |
| 81514 | 1 | 10 | 100 | $260 | $26K |
| 80307 | 5 | 120 | 180 | $60 | $21.2K |
| 87536 | 1 | 10 | 210 | $80 | $17.8K |
Showing 1–10 of 363
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
241 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 34,290 | $70 | $2.3M |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 59,230 | $30 | $2M |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 58,610 | $30 | $2M |
| 87389 | The lab analyst performs a test to screen for human immunodeficiency virus, called HIV. The test screens for antigens of the HIV 1 virus and antibodies to the HIV 1 and HIV 2 viruses using an… | 36,890 | $50 | $2M |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 140,780 | $10 | $1.8M |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 214,800 | $10 | $1.7M |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 33,030 | $40 | $1.5M |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 84,130 | $10 | $1.1M |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 216,830 | $10 | $1.1M |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 179,320 | $10 | $1.1M |
Showing 1–10 of 241
How this provider's Medicaid billing volume and revenue compare to other Indiana providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Indiana median
241 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 20 | 190 | 800 | $40 | $344.7K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 5 | 90 | 1,150 | $60 | $289.6K |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 14 | 140 | 830 | $50 | $265K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 12 | 40 | 160 | $80 | $173.2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 29 | 90 | 390 | $40 | $171.1K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 27 | 50 | 310 | $90 | $169.3K |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 1 | 80 | 340 | $70 | $139.8K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 3 | 50 | 270 | $100 | $125.3K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 109 | 160 | 740 | $60 | $119.1K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 3 | 60 | 80 | $60 | $104.7K |
Showing 1–10 of 241
Other providers in the same ZIP code as Alverno Laboratories, LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Abc Pediatriacs, PC | IN | Pediatrics Physician | $0 | $4.1M |
| Tanesha Williams | IN | Home Health Aide | $0 | $3.6M |
| Williams Eye Institute, PC | IN | Ambulatory Surgical Clinic/Center | $758.7K | $67.9K |
| Ann Williams Md | IN | Ophthalmology Physician | $374.2K | $0 |
| Blake Williams | IN | Ophthalmology Physician | $341.7K | $0 |
| Pastor Llobet | IN | Cardiovascular Disease Physician | $288.8K | $0 |
| Emilie Morphew | IN | Anatomic Pathology & Clinical Pathology Physician | $24.5K | $202.8K |
| Megan Silas | IN | Ophthalmology Physician | $96.1K | $5.5K |
| Huiya Huang | IN | Anatomic Pathology & Clinical Pathology Physician | $82.4K | $1K |
| Chava Landau | IN | Certified Registered Nurse Anesthetist | $82.1K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.